Evolution of Generic Namenda & Its Potential Use for Hyperactivity Disorder

Title: Evolution of Generic Namenda & Its Potential Use for Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD) is a nervous disorder found largely in boys and distinguished by behavioral and learning disorders. This neurological disease is generally dealt with a combination of Ritalin (a central nervous system stimulant) and mental therapy. There is another medication on the horizon in the form of the Alzheimer's drug named Namenda (Memantine HCl). It is presently being viewed as an alternate medicine owing to the manner it has an effect on the human brain.

The generic name Memantine HCl which is now sold under various trade names was first produced in the year 1968 by Eli Lilly and Company. The license of chemical formula was handed over to Forest Laboratories in the early part of 1990s. Memantine was approved for use by common people in 1993. After the FDA approval, Forest Laboratories started out its trading under the name Namenda. Studies on other possible uses of generic Namenda began with a clinical test taken place in June, 2008 by the Massachusetts General Hospital. The objective of the trial was to examine the effects of Namenda on persons with attention deficit disorder. The outcomes of that trial are yet to be disclosed to public.

The principal usage of generic Namenda is to lower the symptoms of patients affected with serious types of Alzheimer's disease. The oral medication is not a cure for the disease itself. However, a report issued by a popular journal of medicine in 2003 presented that it definitely slowed down the rate at which the malady progresses and that sufferers using the drug were more consistent than normal.

Generic Namenda is a medicinal drug taken orally in tablet form. Its elementary role is to act as an anesthetic agent (a drug that causes temporary loss of bodily sensations) on parts of the brain and is formally regarded as an ‘N-methyl-D-aspartic acid receptor antagonist.’ The chief reason why it is considered as a substitute treatment for ADHD is because it does not function as a stimulant drug such as Ritalin or other kinds of prescription drugs.

Nearly all types of drugs recommended by physicians for the treatment of Alzheimer's disease have a common mechanism of action of inhibiting the enzyme known as Acetylcholinesterase from being secreted in the body. On the other hand, Namenda acts in a different manner by obstructing the sensory receptor in the brain that gives rise to a separate enzyme named Glutamate. This particular enzyme has been presently found to be the most important element that contributes to Alzheimer's disease.

Namenda is yet to be given permission by the Food and Drug Administration (FDA) for the use of addressing or healing ADHD and there have been no released issues of the factual effects till now. In the beginning, a patient receiving generic Namenda can go through increased mental disorder for a couple of days till the physician and tolerant come up with the right dosage to take. The most familiar adverse effects of Namenda are cephalalgias (headaches), constipation and lightheadedness.

Back to Memantine

Related Products